RT Journal Article
SR Electronic
T1 Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.16.24305917
DO 10.1101/2024.04.16.24305917
A1 Xie, Ruijie
A1 Seum, Teresa
A1 Sha, Sha
A1 Trares, Kira
A1 Holleczek, Bernd
A1 Brenner, Hermann
A1 Schöttker, Ben
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.16.24305917.abstract
AB Background and Aims To evaluate the potential of improved prediction of the 10-year risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes by adding metabolomic biomarkers to the SCORE2-Diabetes model.Methods Data from 10,257 and 1,039 patients with type 2 diabetes from the UK Biobank (UKB) and the German ESTHER cohort, respectively, were used for model derivation, internal and external validation. A total of 249 metabolites were measured with nuclear magnetic resonance (NMR) spectroscopy. LASSO regression with bootstrapping was used to identify metabolites in sex-specific analyses and the predictive performance of metabolites added to the SCORE2-Diabetes model was primarily evaluated with Harrell’s C-index.Results Seven metabolomic biomarkers were selected by LASSO regression for enhanced MACE risk prediction (three for both sexes, three male- and one female-specific metabolite(s)). Especially albumin and the omega-3-fatty-acids-to-total-fatty-acids-percentage among males and lactate among females improved the C-index. In internal validation with 30% of the UKB, adding the selected metabolites to the SCORE2-Diabetes model increased the C-index statistically significantly (P=0.034) from 0.660 to 0.680 in the total sample. In external validation with ESTHER, the C-index increase was higher (+0.041) and remained statistically significant (P=0.015).Conclusions Incorporating seven metabolomic biomarkers in the SCORE2-Diabetes model enhanced its ability to predict MACE in patients with type 2 diabetes. Given the latest cost reduction and standardization efforts, NMR metabolomics has the potential for translation into the clinical routine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe ESTHER study was funded by the Baden-Wurttemberg state Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany). UK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also had funding from the Welsh assembly government and the British Heart Foundation. The sponsors had no role in data acquisition or the decision to publish the data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UKB received ethical approval from the North-West Multicentre Research Ethics Committee (REC reference: 11/NW/03820). The ESTHER study was approved by the Ethics Committee of the Medical Faculty of the University of Heidelberg (Application number: S-58/2000). Both UKB and ESTHER study are conducted in accordance with the 1964 Helsinki declaration and its later amendments. All study participants of UKB and ESTHER study gave written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from ESTHER is available upon reasonable request that is compatible with participants' informed consent. Data from the UK Biobank (https://www.ukbiobank.ac.uk/) is available to bona fide researchers on application.CIconfidence intervalsCVDcardiovascular diseaseeGFRestimated glomerular filtration rateESTHEREpidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren BevölkerungFDRfalse discovery ratGlycAglycoprotein acetylsGPgeneral practitionerHRhazard ratio; IDI, integrated discrimination improvementLASSOleast absolute shrinkage and selection operatorLC-MS/MSLiquid Chromatography-Mass Spectrometry/Mass SpectrometryMACEmajor adverse cardiovascular eventsMImyocardial infarctionNMRnuclear magnetic resonanceNRInet reclassification index; Omega-3-pct, the Omega-3 fatty acids percentage of total fatty acidsSBPsystolic blood pressureSDstandard deviationUKBUK BiobankVLDL-sizethe average diameter for very low-density lipoprotein particles.